CytomX Therapeutics Faces Listing Rule Issues

Ticker: CTMX · Form: 8-K · Filed: Feb 26, 2025 · CIK: 1501989

Cytomx Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyCytomx Therapeutics, INC. (CTMX)
Form Type8-K
Filed DateFeb 26, 2025
Risk Levelhigh
Sentimentbearish

Sentiment: bearish

Topics: delisting, listing-rules, sec-filing

TL;DR

CytomX might be in trouble with the stock exchange - listing rules are a problem.

AI Summary

CytomX Therapeutics, Inc. filed an 8-K on February 26, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the earliest event reported on February 24, 2025. The company is incorporated in Delaware and its principal executive offices are located in South San Francisco, California.

Why It Matters

This filing indicates potential issues with CytomX Therapeutics' continued listing on a stock exchange, which could impact its stock price and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards is a significant negative event that can lead to severe stock price declines and reduced liquidity.

Key Players & Entities

FAQ

What specific listing rule or standard has CytomX Therapeutics, Inc. failed to satisfy?

The filing does not specify the exact rule or standard that CytomX Therapeutics, Inc. has failed to satisfy, only that a notice has been issued.

What is the earliest date associated with the reported event?

The earliest event reported is dated February 24, 2025.

When was this 8-K form filed with the SEC?

This 8-K form was filed on February 26, 2025.

Where are CytomX Therapeutics, Inc.'s principal executive offices located?

CytomX Therapeutics, Inc.'s principal executive offices are located at 151 Oyster Point Blvd, Suite 400, South San Francisco, California, 94080.

What is the company's IRS Employer Identification Number?

The company's IRS Employer Identification Number is 27-3521219.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on February 26, 2025 regarding CytomX Therapeutics, Inc. (CTMX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing